This is according to a national survey conducted by RAND, a nonprofit, nonpartisan research organization
Success in pharmaceutical litigation depends on identifying, retaining, and preparing qualified medical experts: Relationships with board-certified gastroenterologists who can testify about gastroparesis causation and treatment Access to neuro-ophthalmologists capable of explaining NAION mechanism and linking it to semaglutide use Network of FDA regulatory experts who can opine about warning label adequacy and manufacturer obligations Connections with toxicologists and pharmacologists who know GLP-1 receptor agonist drug mechanisms Ability to prepare experts for deposition and trial testimony, including defending their opinions against Daubert challenges Pharmaceutical defendants always challenge plaintiff expert testimony through Daubert motions arguing that the scientific methodology underlying expert opinions doesnt meet federal evidence standards
Emerging trends in omics research emphasize integration across multiple annotation resources to capture complex biological relationships that single databases alone cannot resolve
Glp1r was only occasionally expressed in other cholinergic cell groups
"Chapter 1 Pharmacokinetics & Pharmacodynamics"
However, in some cases, biopsy is necessary and occasionally, immunohistochemical stains such as melanocyte marker HMB-45 and macrophage marker CD68 may be required to prompt a correct diagnosis
